Tecentriq 1200 mg / 20 mL (Atezolizumab In Pakistan

Tecentriq® 1200 mg/20 mL is an intravenous anticancer medicine containing atezolizumab, a monoclonal antibody that targets the PD-L1 (programmed death-ligand 1) protein. It is an immunotherapy used for the treatment of certain types of cancer. Roche Pakistan lists Tecentriq in 840 mg and 1200 mg IV presentations.

Active Ingredient

• Brand: Tecentriq®
• Active ingredient: Atezolizumab
• Strength: 1200 mg/20 mL
• Concentration: 60 mg/mL
• Dosage form: Solution for intravenous infusion
• Container: Single-dose vial

How Does Tecentriq® Work?

Atezolizumab is a PD-L1 inhibitor. It blocks the interaction of PD-L1 with certain immune-system receptors, helping the immune system recognize and attack cancer cells.

Uses

Depending on the patient's cancer type and clinical circumstances, Tecentriq may be used for certain:

• Non-small cell lung cancers (NSCLC)
• Small cell lung cancer (SCLC)
• Hepatocellular carcinoma (liver cancer)
• Melanoma in combination with specific targeted medicines
• Alveolar soft part sarcoma (ASPS)

The exact approved indication and treatment combination depend on factors such as cancer type, stage, previous treatment, and biomarker results.

Dosage & Administration

Tecentriq is administered by intravenous infusion by a qualified healthcare professional. Depending on the indication, current prescribing information includes dosing schedules such as 1200 mg every 3 weeks. The first infusion is generally administered over 60 minutes; if tolerated, subsequent infusions may be administered over 30 minutes.

The dose and treatment schedule must be determined by an oncologist.

Important Safety Information

Tecentriq can cause immune-mediated side effects because it activates the immune system. These reactions can affect organs including the lungs, liver, intestines, kidneys, skin, thyroid and other endocrine organs, and can occasionally be serious or life-threatening.

Patients should promptly inform their healthcare team about new or worsening symptoms during treatment.

Possible Side Effects

Reported adverse effects can include:

• Fatigue
• Decreased appetite
• Nausea
• Diarrhea
• Rash or itching
• Fever
• Cough or shortness of breath
• Infusion-related reactions

More serious immune-mediated reactions can occur and require medical evaluation.

Storage & Handling

Tecentriq is a temperature-sensitive biological medicine and requires appropriate storage and handling according to the manufacturer's instructions. Roche Pakistan emphasizes uninterrupted cold-chain management for temperature-sensitive Roche products.

Availability in Pakistan

Tecentriq 1200 mg/20 mL IV is listed by Roche Pakistan as a pharmaceutical product. Roche Pakistan also provides an authorized distributor network for genuine Roche medicines in Pakistan.

Availability can be arranged subject to current stock and prescription requirements in major cities including Karachi, Lahore, Islamabad, Rawalpindi, Peshawar, Multan, Faisalabad, Hyderabad, Gujranwala, Sialkot, Bahawalpur, Sukkur, Larkana and other areas of Pakistan.

Prescription Information

Tecentriq is a specialist prescription oncology medicine and should only be administered under the supervision of an oncologist or appropriately qualified healthcare professional.